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EFFECT OF ORAL ALENDRONATE ON BONE MINERAL DENSITY AND THE INCIDENCE OF 
FRACTURES IN POSTMENOPAUSAL OSTEOPOROSIS
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Abstract
 
Background.
 
Postmenopausal osteoporosis
is a serious health problem, and additional treatments
are needed.
 
Methods.
 
We studied the effects of oral alendronate,
an aminobisphosphonate, on bone mineral density and
the incidence of fractures and height loss in 994 women
with postmenopausal osteoporosis. The women were
treated with placebo or alendronate (5 or 10 mg daily for
three years, or 20 mg for two years followed by 5 mg for
one year); all the women received 500 mg of calcium dai-
ly. Bone mineral density was measured by dual-energy
x-ray absorptiometry. The occurrence of new vertebral
fractures and the progression of vertebral deformities
were determined by an analysis of digitized radiographs,
and loss of height was determined by sequential height
measurements.
 
Results.
 
The women receiving alendronate had sig-
niﬁcant, progressive increases in bone mineral density
at all skeletal sites, whereas those receiving placebo
had decreases in bone mineral density. At three years,
the mean (
 

 
SE) differences in bone mineral density be-
tween the women receiving 10 mg of alendronate daily
and those receiving placebo were 8.8
 

 
0.4 percent in
the spine, 5.9
 

 
0.5 percent in the femoral neck, 7.8
 

 
0.6
percent in the trochanter, and 2.5
 

 
0.3 percent in the to-
tal body (P
 

 
0.001 for all comparisons). The 5-mg dose
was less effective than the 10-mg dose, and the regi-
men of 20 mg followed by 5 mg was similar in efﬁcacy
to the 10-mg dose. Overall, treatment with alendronate
was associated with a 48 percent reduction in the pro-
portion of women with new vertebral fractures (3.2 per-
cent, vs. 6.2 percent in the placebo group; P
 

 
0.03), a
decreased progression of vertebral deformities (33 per-
cent, vs. 41 percent in the placebo group; P
 

 
0.028),
and a reduced loss of height (P
 

 
0.005) and was well
tolerated.
 
Conclusions.
 
Daily treatment with alendronate pro-
gressively increases the bone mass in the spine, hip,
and total body and reduces the incidence of vertebral
fractures, the progression of vertebral deformities, and
height loss in postmenopausal women with osteoporosis.
(N Engl J Med 1995;333:1437-43.)
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P
 
OSTMENOPAUSAL osteoporosis is a common dis-
order characterized by an increase in bone resorp-
tion relative to bone formation, generally in conjunction
with an increased rate of bone turnover.
 
1
 
 The progres-
sive decrease in bone mass leads to an increased sus-
ceptibility to fractures, which result in substantial mor-
bidity and mortality.
 
2
 
 Vertebral fractures are important
not only because they can cause pain, kyphosis, and
height loss but also because they predict subsequent,
nonvertebral fractures independently of bone mineral
density.
 
3
 
 Although there are several risk factors for
fractures, reduced bone mineral density is the strongest
predictor.
 
4
 
 Thus, the ultimate goal of pharmacologic
treatment in women with postmenopausal osteoporosis
is to reduce the risk of fractures by increasing bone
mass of normal quality.
The clinically useful bisphosphonates are synthetic
analogues of inorganic pyrophosphate, an endogenous
regulator of bone turnover that inhibits bone resorption
and mineralization in vitro.
 
5
 
 All bisphosphonates have
a high afﬁnity for hydroxyapatite but, unlike pyrophos-
phate, are resistant to metabolism by endogenous phos-
phatases.
 
5,6
 
 Bisphosphonates are capable of inhibiting
bone mineralization at roughly equivalent doses; how-
ever, their potencies for the inhibition of bone resorp-
tion depend on the unique chemical structure of their
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side chains.
 
7
 
 The four-carbon amino side chain of alen-
dronate conveys a very high potency, which in turn per-
mits effective inhibition of osteoclast-mediated bone
resorption at doses that do not impair bone mineraliza-
tion,
 
6
 
 even with daily doses, which is not the case with
etidronate.
 
8,9
 
 Treatment with alendronate speciﬁcally
inhibits increased bone resorption and thereby normal-
izes the rate of bone turnover.
 
10
 
 Preclinical evaluations
of alendronate in animals with osteoporosis have docu-
mented greater bone strength in accordance with in-
creased bone mass,
 
11,12
 
 indicating the normal quality of
alendronate-treated bone. Iliac-crest biopsies in pa-
tients treated with alendronate for up to three years
show normal bone without evidence of mineralization
defects.
 
13
 
In 1990 two multicenter dose-ranging studies were
initiated in several countries to determine the efﬁcacy
of continuous oral alendronate therapy in postmeno-
pausal women with osteoporosis. These randomized,
double-blind, placebo-controlled studies had identical
designs. Bone mineral density of the spine was chosen
as the primary end point on the basis of epidemiologic
evidence demonstrating a strong and consistent rela-
tion between low bone mass and an increased risk of
fracture.
 
14,15
 
 The studies also evaluated the incidence
of vertebral fractures, the progression of vertebral
deformities, height loss, and the incidence of adverse
effects. We report the combined results of these two
trials.
 
M
 
ETHODS
 
Study Population
 
One multicenter study was conducted in the United States, and
the other in Australia, Canada, Europe, Israel, Mexico, New Zea-
land, and South America. Women who were 45 to 80 years old and
postmenopausal (
 

 
5 years since menopause) with osteoporosis (de-
ﬁned as a bone mineral density of the lumbar spine that was at least
2.5 SD below the mean value in premenopausal white women) were
eligible for participation. These enrollment criteria were selected to
represent the general population of women with osteoporosis (i.e.,
women with a low bone mass, with or without fractures). We exclud-
ed women with other causes of osteoporosis (e.g., treatment with
glucocorticoids) or other disorders of bone and mineral metabolism
(e.g., vitamin D deﬁciency, Paget’s disease, or hyperparathyroidism);
active peptic ulcer disease, abnormal renal function (serum creati-
nine level, 
 

 
1.5 mg per deciliter [130 
 
m
 
mol per liter]), or abnormal
hepatic function; abnormalities of the lumbar spine precluding the
assessment of bone mineral density at a minimum of three lumbar
vertebrae or a history of hip fracture; or any prior treatment with
bisphosphonates or treatment within the preceding 12 months with
estrogen, progestin, calcitonin, ﬂuoride, or an anabolic steroid.
Women were not excluded on the basis of race. All the women pro-
vided written informed consent, and the study protocols were
approved by the institutional review board at each participating
center.
 
Treatment
 
The women were randomly assigned to receive placebo (40 percent
of the women) or 5, 10, or 20 mg of alendronate per day (20 percent
in each dose group) for two years, to be followed by open-label ther-
apy during the third year. Before any of the women had reached the
24-month visit, the protocol was modiﬁed to include a third year of
double-blind therapy, and the women receiving 20 mg of alendronate
per day were switched (blindly) to a dose of 5 mg per day for the third
year. This change was made because the results of another study had
demonstrated that a dose of 20 mg per day was more than necessary
to obtain the maximal increase in bone mineral density.
 
16
 
 All the
women received a daily supplement of calcium carbonate providing
500 mg of elemental calcium.
 
End Points
 
The bone mineral density of the lumbar spine, femoral neck, tro-
chanter, forearm, and total body was measured by dual-energy x-ray
absorptiometry with the use of Hologic QDR-1000 or 1000/W (Ho-
logic, Waltham, Mass.), Lunar DPX-L (Lunar, Madison, Wis.), or
Norland XR-26 (Norland, Fort Atkinson, Wis.) densitometers. All
scans were reviewed (without knowledge of the treatment assign-
ment) at a central facility, which provided factors to correct for cali-
bration drift in the machines as necessary.
Lateral spine ﬁlms were obtained at base line and after one, two,
and three years of therapy to detect vertebral fractures and the pro-
gression of vertebral deformities. Analysis of these end points was
based on the change from base line (or the ﬁrst available ﬁlm) to the
latest follow-up ﬁlm. Films of the thoracic and lumbar spine were
obtained with the standard values for target-to-ﬁlm distance and cen-
tering used at each study center. The ﬁlms were sent to the radiology
center, where vertebral heights were determined by observers unaware
of the treatment assignment or ﬁlm sequence. All ﬁlms from each
woman were digitized at the same time. Three points were placed
along the superior edge and three along the inferior edge of each ver-
tebra from the fourth thoracic vertebra (T4) to the ﬁfth lumbar ver-
tebra (L5), demarcating the anterior, middle, and posterior heights of
each vertebral body. A computer mouse with cross-hairs and a com-
mercially available digitization board were used to enter the data as
X and Y coordinates, and vertebral heights were calculated to the
nearest 0.1 mm with the use of computer software. Corrections for
magniﬁcation errors were made when appropriate.
The presence of vertebral fractures at base line (previous fractures)
was determined by comparing each woman’s base-line vertebral-
height ratios with those of a reference group.
 
17
 
 The ratios were calcu-
lated as follows: the anterior and middle heights were compared with
the posterior height of the same vertebra, and the posterior height
was compared with the posterior height of an adjacent vertebra. Any
vertebral-height ratio more than 3 SD below the corresponding refer-
ence ratio was considered to be a previous vertebral fracture.
 
17
 
 A new
fracture was deﬁned as a reduction of at least 20 percent, with an ab-
solute decrease of at least 4 mm, in the height of any vertebral body
between base line and follow-up.
Vertebral deformities were assessed with the Spine Deformity In-
dex, which was developed as a continuous measure of vertebral de-
formities in patients with a history of vertebral fractures. The index
sums deformations of multiple vertebrae into a single numerical val-
ue.
 
18
 
 Each vertebral height (T5 through L5) is divided by the corre-
sponding T4 height (anterior, middle, or posterior) to generate a max-
imum of 39 vertebral-height ratios, which are corrected for differences
in stature. Each ratio is then compared with population norms, and
the absolute differences for ratios that fall below the minimal popula-
tion norm are added, to arrive at the total Spine Deformity Index. We
expected that a sizable proportion of the women with osteoporosis in
our study would have no measurable deformities initially (i.e., a Spine
Deformity Index of zero) and that no deformities would develop dur-
ing the study. Hence, the primary use of the Spine Deformity Index
was to compare the proportion of women in each group with in-
creased indexes during the study.
Height was measured at base line and at 3, 6, 9, 12, 18, 24, 27, 30,
and 36 months with a Harpenden stadiometer (Holtain, Crymmych,
Pembrookshire, United Kingdom), which measures height to the near-
est millimeter. Three measurements were obtained for each woman at
each time point, and two additional measurements were made if any
two values differed by more than 4 mm. The value for height was the
average of all three or ﬁve measurements obtained at each visit.
All reported symptomatic nonvertebral fractures were recorded, with
no attempt to exclude fractures on the basis of the degree of trauma.
 
Statistical Analysis
 
From the outset, the plan was to pool the data from the two, iden-
tically designed studies and from the three alendronate groups in each
study, since we anticipated that neither trial alone, nor any one dose
group, would be sufﬁciently large to allow the detection of a signiﬁ-
cant effect of alendronate on the incidence of new fractures.
Changes in bone mineral density at each site (expressed as the per-
centage of increase or decrease from the base-line value) were calcu-
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lated at 3, 6, 12, 18, 24, 30, and 36 months. All analyses reﬂect the
correction factors calculated at the central facility, which were deter-
mined from standard phantom spine measurements made during the
study.
For the analysis of the proportion of women with one or more new
vertebral fractures, the Breslow–Day test was used to determine wheth-
er there was any interaction between treatment group and study (since
there were two studies). Because no interaction was evident (P
 

 
0.43),
the study designs were identical, and the data pooling was speciﬁed in
advance, the pooling of data from the two studies was valid. After the
data had been pooled, the Cochran–Mantel–Haenszel test was used to
compare the placebo group with the alendronate group. Estimates of
the relative risk associated with alendronate as compared with placebo
and 95 percent conﬁdence intervals were computed.
A chi-square test was used to compare the proportions of women
with progressive vertebral deformities (i.e., women with an increased
Spine Deformity Index) in the placebo and alendronate groups. For
the analysis of changes in height from base line, we used an analysis-
of-variance model that included terms for the treatment group, center,
and interaction between the treatment and the center. This last term
was removed from the analysis, since there was no statistical evidence
of such an interaction. Slopes (for changes in height over time) were
calculated for women who had at least three height measurements and
were evaluated in a fashion similar to that described above, except that
a weighted analysis of variance was used, with the weights inversely
proportional to the variance of the estimated slope for each woman.
 
19
 
Nonvertebral fractures were analyzed with the Cox proportional-haz-
ards model, with each of the two studies as a stratiﬁcation factor.
All analyses of the efﬁcacy of alendronate were based on the inten-
tion-to-treat principle; that is, all women who had at least one meas-
urement after randomization were included in the evaluation, irre-
spective of whether they were still taking the study drug. Treatment
effects for certain prespeciﬁed patient characteristics (e.g., age and
the presence or absence of a vertebral fracture at base line) were sum-
marized for all end points, but no P values were computed.
 
R
 
ESULTS
 
The base-line characteristics of the women in the
treatment and placebo groups were similar (Table 1),
and there were no differences between the two studies
in the risk factors for fracture (data not shown). A total
of 87.4 percent of the women were white, 0.4 percent
were black, and 12.2 percent were of other races. Of
the 994 women randomly assigned to treatment, 909
(91 percent) completed at least one year of the study.
Paired spine ﬁlms were analyzed for 881 (97 percent)
of these women. Of the other 28 women, 21 had ﬁlms
that could not be digitized because of their poor quali-
ty, 4 had follow-up ﬁlms that could not be found, and
3 declined follow-up radiography. The 113 women not
included in the analysis of vertebral fractures did not
differ from the other 881 women (data not shown).
About 20 percent of the women in each group had ver-
tebral fractures at base line (Table 1).
The Spine Deformity Index, which requires paired
ﬁlms with at least 13 vertebrae that can be fully evalu-
ated, was calculated for 835 (95 percent) of the women
included in the vertebral-fracture analysis. A total of
921 women had height values recorded at base line and
at least one follow-up visit for the analysis of absolute
loss of height; 902 women with values for at least three
time points were included in the analysis of the rate of
change in height. All women were included in the anal-
ysis of nonvertebral fractures.
 
Bone Mineral Density
 
There were signiﬁcant increases in the bone mineral
density of the spine, femoral neck, trochanter, and total
body at 36 months in all three alendronate groups, and
signiﬁcant losses at all sites in the placebo group (Fig.
1). The 10-mg dose was signiﬁcantly more effective than
the 5-mg dose at all skeletal sites and was as effective as
20 mg followed by 5 mg. The mean (
 

 
SE) differences
in bone mineral density between the women receiving
10 mg of alendronate daily and those receiving placebo
were 8.8
 

 
0.4 percent in the spine, 5.9
 

 
0.5 percent in
the femoral neck, 7.8
 

 
0.6 percent in the trochanter, and
2.5
 

 
0.3 percent in the total body (P
 

 
0.001 for all com-
parisons). At two years, 10 mg was as effective as 20 mg
(Fig. 1). As expected with an antiresorptive agent, the
bone mineral density at each site increased most rapidly
during the ﬁrst six months of treatment.
The 10-mg dose of alendronate resulted in increases
in bone mineral density at all sites during all three
years, although the increase in total-body bone min-
eral density during year 3 was not signiﬁcant (Fig. 1).
In contrast, the bone mineral density in the spine, hip,
and total body did not increase signiﬁcantly during
the third year in the patients treated with 5 mg of
alendronate per day or 20 mg followed by 5 mg. Thus,
the progressive increases in bone mineral density at
each site during the 36-month study period were most
marked in response to 10 mg of alendronate per day,
with no plateau in the effect during the entire 3-year
study period at either the spine or the hip. In the mid-
forearm, an almost entirely cortical site, the 10-mg dose
also resulted in 2.2
 

 
0.4 percent greater bone mineral
density than placebo (P
 

 
0.001).
The increases in bone mineral density in the spine
were similar regardless of the bone mineral density,
rate of bone turnover, age, or creatinine clearance at
 
*The body-mass index was calculated as the weight in kilograms divided by the square of
the height in meters. Measurements of bone mineral density are shown according to the site
of the measurement and the type of densitometer.
†Data are for women with a Spine Deformity Index of zero.
‡Data are for women with a Spine Deformity Index higher than zero.
 
Table 1. Base-Line Characteristics of the 881 Women Included
in the Analysis of Vertebral Fractures.
 
*
 
C
 
HARACTERISTIC
 
P
 
LACEBO
 
 G
 
ROUP
 
(N
 

 
355)
A
 
LENDRONATE
 
 G
 
ROUP
 
(N
 

 
526)
 
Mean age (yr) 64 64
Mean yr since menopause 17 16
Mean body-mass index 24.1 24.2
Vertebral fractures (% of women) 21.2 20.2
No vertebral deformities (% of women)† 52.6 57.0
Mean Spine Deformity Index‡ 0.49 0.48
Mean bone mineral density (g/cm
 
2
 
)
Lumbar spine
Hologic
Lunar
Norland
Femoral neck
Hologic
Lunar
Norland
Trochanter
Hologic
Lunar
Norland
Total body
Hologic
Lunar
Norland
0.71
0.82
0.68
0.60
0.74
0.67
0.53
0.62
0.56
0.93
0.95
1.03
0.71
0.81
0.67
0.60
0.72
0.66
0.52
0.61
0.53
0.92
0.94
1.04
Mean interval between ﬁlms (yr) 2.8 2.8
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base line. Over 96 percent of the women treated with
10 mg of alendronate for three years had measurable
increases in bone mineral density in the spine (data not
shown).
 
Vertebral Fractures
 
During the study, 22 of the 355 women in the place-
bo group (6.2 percent) had at least one new vertebral
fracture, as compared with 17 of the 526 women in the
combined alendronate groups (3.2 percent, P
 

 
0.03)
(Table 2). Only two women had new vertebral fractures
only in vertebrae with previous fractures. The relative
risk of a new fracture among the women treated with
alendronate, as compared with those receiving placebo,
was 0.52 (95 percent conﬁdence interval, 0.28 to 0.95).
This decreased risk among the women receiving alen-
dronate was found in both studies and in women strat-
iﬁed according to age (less than 65 years or 65 years or
older) or the presence or absence of a previous verte-
bral fracture (Table 2). The risk of a vertebral fracture
was also decreased in all dose groups, with new verte-
bral fractures in 2.9 percent of the women receiving
5 mg of alendronate, 2.8 percent of those receiving
10 mg, and 4.1 percent of those receiving 20 mg fol-
lowed by 5 mg, as compared with 6.2 percent of the
women in the placebo group.
Among the women who had new vertebral fractures,
the proportion with two or more fractures was much
lower in the combined alendronate groups (18 percent)
than in the placebo group (68 percent). On an absolute
basis, 4.2 percent of the women receiving placebo (15
of 355) had two or more vertebral fractures, as com-
pared with 0.6 percent of those treated with alendro-
nate (3 of 526). Because of the combination of fewer
affected women and fewer fractures per woman, the
number of vertebral fractures per 100 women was sub-
stantially lower in the combined alendronate groups
than in the placebo group (4.2 vs. 11.3). Among the
women with vertebral fractures, the ratio of wedge or
crush fractures to end-plate fractures was higher in
the placebo group than in the com-
bined alendronate groups (data not
shown).
 
Spine Deformity Index
 
The Spine Deformity Index in-
creased in 33 percent of the women
receiving alendronate but in 41 per-
cent of those receiving placebo
(P
 

 
0.028). This beneﬁcial effect of
alendronate was consistent in both
studies, in women younger than 65
or 65 or older, and in women with or
without vertebral deformities at base
line (data not shown). There was a
difference of borderline signiﬁcance
(P
 

 
0.054 by the Wilcoxon rank-
sum test) in the distribution of the
change from the base-line Spine
Deformity Index in the placebo and
alendronate groups. The mean
change in the Spine Deformity In-
dex was 0.08
 

 
0.02 in the placebo
group and 0.04
 

 
0.01 in the alendro-
nate group.
 
Height
 
The mean loss of height after
three years of treatment was 35 per-
cent less in the alendronate group
than in the placebo group (3.0 mm
vs. 4.6 mm, P
 

 
0.005). The effect of
alendronate in preventing loss of
height was greater in the older wom-
en (
 

 
65 years) and in the subgroup
with previous fractures than in the
younger women or the subgroup
without previous fractures (data not
shown). The annualized rate of
height loss was about 40 percent
lower in the women treated with
alendronate than in those receiving
 
Figure 1. Mean (SE) Changes in Bone Mineral Density from Base-Line Values in
Women with Postmenopausal Osteoporosis Receiving Alendronate or Placebo for
Three Years.
Data are shown for bone mineral density (measured by dual-energy x-ray absorpti-
ometry) of the spine, femoral neck, trochanter, and total body. Data for the alendro-
nate group are shown according to the dose: 5 or 10 mg per day for three years or
20 mg per day for two years followed by 5 mg per day in year 3.
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placebo, resulting in a difference between the groups of
0.7 mm per year (P0.001).
Loss of height in the women without new vertebral
fractures was small and similar in the treatment and
placebo groups (2.8 and 3.3 mm, respectively) (Fig. 2).
Among the women with new vertebral fractures, how-
ever, those in the placebo group lost a mean of 23.3 mm
in height, whereas the mean loss of height in the alen-
dronate group (5.9 mm) was only slightly greater than
the mean loss in the women without new fractures.
Nonvertebral Fractures
Nonvertebral fractures occurred in 83 women, with a
trend toward a reduced number of fractures in the
alendronate group. Of the 397 women in the placebo
group, 38 had a total of 47 nonvertebral fractures dur-
ing 1015 patient-years of follow-up, whereas 45 of the
597 alendronate-treated women had a total of 46 non-
vertebral fractures during 1525 patient-years of follow-
up. In the placebo group, the cumulative incidence of
women with nonvertebral fractures after three years
was 10.7 percent, with an overall rate of 3.7 women with
fractures per 100 patient-years at risk. In the alendro-
nate group, the cumulative incidence was 8.5 percent,
with an overall rate of 3.0 women with fractures per 100
patient-years at risk. The estimated risk of nonvertebral
fractures in the women treated with alendronate was
0.79 (95 percent conﬁdence interval, 0.52 to 1.22). The
difference in the cumulative proportions of women
without nonvertebral fractures in the alendronate and
placebo groups appeared to increase in the third year
(Fig. 3). Table 3 shows the data for all nonvertebral
fractures. There were no reports of stress fractures,
fracture malunion, or delayed healing of fractures.
Adverse Effects
Alendronate was generally well tolerated, with no
greater clinical or laboratory evidence of adverse ef-
fects than with placebo. Overall, 16.3 percent of the
women discontinued therapy, with similar frequencies
in the placebo group and all three alendronate groups
(Table 4). Discontinuation was due to clinical adverse
effects in 6.0 percent of the women receiving placebo,
5.4 percent of those receiving 5 mg of alendronate, 4.1
percent of those receiving 10 mg, and 8.0 percent of
those receiving 20 mg for two years followed by 5 mg
in the third year. Dose-dependent upper gastrointes-
tinal irritation is the primary side effect associated with
several other bisphosphonates, which are administered
at higher doses.20,21 The women in the placebo group
and all three alendronate groups had similar rates of
adverse upper gastrointestinal effects, resulting in the
discontinuation of treatment in only 2.0 percent of the
women receiving placebo, 3.5 percent of those receiving
5 mg of alendronate, 1.0 percent of those receiving 10
mg, and 2.0 percent of those receiving 20 mg followed
by 5 mg. The most common adverse effects considered
to be drug-related by the blinded investigators were ab-
dominal pain (in 6.6 percent of the women receiving 10
mg of alendronate and 4.8 percent of those receiving
placebo), musculoskeletal pain (in 4.1 and 2.5 percent,
respectively), nausea (in 3.6 and 4.0 percent), dyspepsia
(in 3.6 and 3.5 percent), constipation (in 3.1 and 1.8 per-
cent), and diarrhea (in 3.1 and 1.8 percent).
DISCUSSION
Daily treatment with oral alendronate for three years
resulted in increases in the bone mineral density of the
spine, hip, and total body in women with postmeno-
pausal osteoporosis, and these effects were associated
with reductions in the incidence of vertebral fractures,
vertebral deformities, and loss of height, as well as a
trend toward a reduction in the incidence of fractures
at nonvertebral sites. The 10-mg dose produced pro-
gressive increases in bone mineral density, which were
larger than the increases associated with the 5-mg dose
at all skeletal sites and at all time points after six
months. The efﬁcacy of 10 mg of alendronate per day
was similar to that of 20 mg per day for two years and
did not plateau during up to three years of therapy —
a ﬁnding consistent with the reversal of a negative bone
balance at the level of individual remodeling units. Al-
though 20 mg per day for two years followed by 5 mg
*The numbers of women with and without previous fractures do not sum to 881, because
only women with pretreatment ﬁlms that could be fully evaluated were included in the base-
line analysis of fractures.
†P0.03, relative risk 0.52 (95 percent conﬁdence interval, 0.28 to 0.95).
Table 2. Women with New Vertebral Fractures during the Three-
Year Study Period.*
GROUP OF WOMEN PLACEBO GROUP ALENDRONATE GROUP
% of women with fractures (no./total no.)
All 6.2 (22/355) 3.2 (17/526)†
Age, 65 yr 4.7 (9/190) 3.7 (11/294)
Age, 65 yr 7.9 (13/165) 2.6 (6/232)
With previous fractures 19.1 (13/68) 13.4 (13/97)
Without previous fractures 2.0 (5/253) 1.0 (4/384)
In U.S. study 4.5 (8/177) 1.6 (4/258)
In multinational study 7.9 (14/178) 4.9 (13/268)
Figure 2. Mean (SE) Changes in Height from Base-Line Val-
ues among Women with or without New Vertebral Fractures in
the Alendronate and Placebo Groups.
Changes in height were calculated as the mean of three to ﬁve
measurements per woman, made with a Harpenden stadiome-
ter. The data for the women in the three alendronate groups
have been pooled.
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per day in the third year is a 50 percent greater cumu-
lative dose than 10 mg per day for three years, the
greater increase in bone mineral density during the
third year in the 10-mg group indicates that the current
dose of alendronate, not the total or cumulative dose,
results in the changes in bone mass. All three doses in-
creased the bone mass at all sites, including the total
body, which is consistent with a systemic effect rather
than a redistribution of the bone mass from cortical to
trabecular bone. Continuous therapy with 10 mg of
alendronate per day provided maximal efﬁcacy, was
well tolerated, and is therefore the optimal dose for the
treatment of osteoporosis in postmenopausal women.
Most prospective, randomized trials with fractures as
an end point have recruited women who had multiple
vertebral fractures at base line and were therefore at
very high risk for subsequent fractures.22-29 Although
these women had higher rates of fracture than the wom-
en in our study,14 the applicability of the results of these
trials to the general population of women with oste-
oporosis may be limited. A recent positive study of the
effects of vitamin D3 and calcium on hip fractures en-
rolled only elderly institutionalized women, nearly half
of whom had biochemical evidence of vitamin D deﬁ-
ciency.30 In contrast, the women in the two studies re-
ported here were selected because of decreased bone
mineral density in the lumbar spine but were not re-
quired to have a history of vertebral or other fractures.
Therefore, the results of these studies should be applica-
ble to most women with postmenopausal osteoporosis.
The selection of the optimal dose of alendronate for
the treatment of osteoporosis was based on bone min-
eral density, rather than fractures, as the primary end
point, since dose-ranging studies that used fractures as
the primary end point would require many more wom-
en. To verify the hypothesis that increases in bone mass
induced by alendronate would reduce the incidence of
fractures, we compared all three alendronate groups
with the placebo group. Because the regimen of 10 mg
of alendronate per day for three years produced a
greater increase in bone mineral density than the other
doses (the women in the 10-mg group had 8.8 percent
greater density at the spine than those in the placebo
group), as well as a larger decrease in the incidence of
vertebral fractures (55 percent), the pooling of the dose
groups may underestimate the efﬁcacy of the 10-mg
dose in preventing fractures.
A number of previous trials have used fracture rates
as the primary unit of analysis in determining the efﬁ-
cacy of treatment.22-25,28,31 In contrast, we used the num-
ber of women with new vertebral fractures, since multi-
ple fractures in the same woman are not independent
events.32 Nevertheless, fracture rates are of interest.
Treatment with alendronate, as compared with place-
bo, decreased the average number of vertebral fractures
per woman by 63 percent. The decrease in the number
of fractures and the smaller proportions of crush and
wedge fractures account for the much smaller loss of
height among the women with new fractures in the
alendronate group than among the women with new
fractures in the placebo group.
We found a trend toward a decreased proportion of
women with new nonvertebral fractures in the alendro-
nate group, with a 21 percent reduction in absolute risk
among the women treated with alendronate, as com-
pared with those receiving placebo. The use of pooled
data on nonvertebral fractures as an indication of the
efﬁcacy of treatment represents a post hoc analysis and
should be viewed with some caution. Nevertheless, the
reduction in new nonvertebral fractures in the alen-
dronate group is consistent with the progressive in-
creases in the bone mineral density of the hip and total
body induced by treatment with alendronate, as well as
with the reduction in vertebral fractures. These results
suggest that alendronate increases bone strength at ap-
pendicular sites, as well as in the axial skeleton.
The results of these trials are consistent both inter-
nally and with prospective epidemiologic studies of the
relation between bone mineral density of the lumbar
spine and the risk of vertebral fracture.14,15 The women
in the placebo group with the lowest base-line bone
mineral density of the lumbar spine had the highest in-
Figure 3. Cumulative Proportion of Women without Nonvertebral
Fractures.
The data were calculated by the life-table method. The data for
the women in the three alendronate groups have been pooled.
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Table 3. Women with New Nonvertebral Fractures and Sites of
Fracture during the Three-Year Study Period.
NONVERTEBRAL FRACTURES
PLACEBO GROUP
(N  397)
ALENDRONATE GROUP
(N  597)
No. of women (%) 38 (9.6) 45 (7.5)
No. of fractures 47 46 
Site of fracture — no. of women (%)
Hip
Pelvis
Wrist or forearm
Upper arm
Leg or patella
Rib
Ankle, foot, or toe
Hand or ﬁnger
Clavicle or sternum
Shoulder
Face or skull
3 (0.8)
4 (1.0)
16 (4.0)
4 (1.0)
6 (1.5)
6 (1.5)
6 (1.5)
1 (0.3)
1 (0.3)
0 
0 
1 (0.2)
0 
8 (1.3)
2 (0.3)
4 (0.7)
6 (1.0)
15 (2.5)
1 (0.2)
4 (0.7)
2 (0.3)
3 (0.5)
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cidence of new vertebral fractures, the highest rate of
progression of vertebral deformities, and the greatest
loss in height during the study, whereas the women
with the highest base-line bone mineral density of the
spine had the lowest values for these three end points
(data not shown). In addition, the overall increase in
spine bone mineral density in the alendronate group
(approximately 8 percent, as compared with a decrease
in the placebo group) was associated with an almost 50
percent decrease in the proportion of women with new
vertebral fractures. These ﬁndings conﬁrm the results
of other studies indicating that the relative risk of a ver-
tebral fracture approximately doubles for each reduc-
tion in spine bone mineral density equivalent to 1 SD
(approximately 10 percent).14,15
In summary, daily treatment with oral alendronate
progressively increases the bone mass of the spine, hip,
and total body and reduces the risk of vertebral frac-
tures, the progression of vertebral deformities, and
height loss in postmenopausal women with osteoporosis.
We are indebted to Ms. Ann Barash for assistance in the prepara-
tion of the manuscript and to the study nurses and technicians for as-
sistance in conducting the studies.
APPENDIX
In addition to the authors, the following investigators were mem-
bers of the Alendronate Phase III Osteoporosis Treatment Study
Group: M.Z. Baker, Oklahoma City; M. Bliziotes, Portland, Oreg.;
H.G. Bone III, Detroit; R. Correa-Rotter and J.C. Peña, Mexico
City; D.C. Cumming, Edmonton, Alta., Canada; J.P. Devogelaer and
C. Nagant de Deuxchaisnes, Brussels, Belgium; R.D. Emkey, Read-
ing, Pa.; P. Geusens, Diepenbeek, Belgium; D. Hosking, Nottingham,
United Kingdom; P. Jaeger, Bern, Switzerland; C.C. Johnston, Jr., In-
dianapolis; J.M. Kaufman and A. Vermeulen, Ghent, Belgium; M.O.
Leite, São Paulo, Brazil; J. León, Bogotá, Colombia; R. Samuel, Tel
Aviv, Israel; R. Marcus and M.L. Villa, Palo Alto, Calif.; H. McIl-
wain, J.C. Silverﬁeld, and J.L. Miller, Tampa, Fla.; C. J. Menkes, Par-
is; P. J. Meunier, Lyon, France; I.R. Reid, Auckland, New Zealand;
A. Romanowicz, Buenos Aires, Argentina; R.D. Tonino, Burlington,
Vt.; J. Tucci, Providence, R.I.; R.D. Wasnich, Honolulu; N.B. Watts,
Atlanta; and R.S. Weinstein and A.L. Mulloy, Augusta, Ga. Radiology
Center, Bad Pyrmont, Germany: T. Bruckner and W. Pollähne. Bone Den-
sitometry Center, Portland, Oreg.: E.S. Orwoll, S. Oviatt-Orwoll, and
K. Linton. Merck Research Laboratories, Rahway, N.J.: C. Arena, K. Ple-
zia, C. Peverly, C.D. Maibach, D.R. Shapiro, D.E. Thompson, and
R. Tierney. 
REFERENCES
1. Riggs BL, Melton LJ III. The prevention and treatment of osteoporosis.
N Engl J Med 1992;327:620-7.
2. Consensus development conference: diagnosis, prophylaxis, and treatment
of osteoporosis. Am J Med 1993;94:646-50.
3. Burger H, van Daele PLA, Algra D, et al. Vertebral deformities as predictors
of non-vertebral fractures. BMJ 1994;309:991-2.
4. Leichter I, Margulies JY, Weinreb A, et al. The relationship between bone
density, mineral content, and mechanical strength in the femoral neck. Clin
Orthop 1982;163:272-81.
5. Fleisch H. Bisphosphonates: pharmacology and use in the treatment of tu-
mor-induced hypercalcaemic and metastatic bone disease. Drugs 1991;42:
919-44.
6. Schenk R, Eggli P, Fleisch H, Rosini S. Quantitative morphometric evalua-
tion of the inhibitory activity of new aminobisphosphonates on bone resorp-
tion in the rat. Calcif Tissue Int 1986;38:342-9.
7. Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P. Structure-
activity relationships of various bisphosphonates. Calcif Tissue Int 1983;35:
87-99.
8. Marcus R. Cyclic etidronate: has the rose lost its bloom? Am J Med 1993;
95:555-6.
9. Axelrod DW, Teitelbaum SL. Results of long-term cyclical etidronate ther-
apy: bone histomorphometry and clinical correlates. J Bone Miner Res
1994;9:Suppl 1:S136. abstract.
10. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new
biochemical markers of bone turnover in late postmenopausal osteoporotic
women in response to alendronate treatment. J Clin Endocrinol Metab
1994;79:1693-700.
11. Guy JA, Shea M, Peter CP, Morrissey R, Hayes WC. Continuous alen-
dronate treatment throughout growth, maturation, and aging in the rat re-
sults in increases in bone mass and mechanical properties. Calcif Tissue Int
1993;53:283-8.
12. Balena R, Toolan BC, Shea M, et al. The effects of 2-year treatment with
the aminobisphosphonate alendronate on bone metabolism, bone histomor-
phometry, and bone strength in ovariectomized nonhuman primates. J Clin
Invest 1993;92:2577-86.
13. Arlot MC, Meunier PJ, Chavassieux P, et al. Effects of long-term alendro-
nate treatment for postmenopausal osteoporosis on bone histomorphome-
try. J Bone Miner Res 1995;10:Suppl 1:S199. abstract.
14. Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and
bone mass predict vertebral fracture incidence in women. Ann Intern Med
1991;114:919-23.
15. Melton LJ III, Atkinson EJ, O’Fallon WM, Wahner HW, Riggs BL. Long-
term fracture prediction by bone mineral assessed at different skeletal sites.
J Bone Miner Res 1993;8:1227-33.
16. Chesnut CH III, McClung MR, Ensrud KE, et al. Alendronate treatment of
the postmenopausal osteoporotic woman: effect of multiple dosages on
bone mass and bone remodeling. Am J Med 1995;99:144-52.
17. Melton LJ III, Lane AW, Cooper C, Eastell R, O’Fallon WM, Riggs BL.
Prevalence and incidence of vertebral deformities. Osteoporos Int 1993;3:
113-9.
18. Minne HW, Leidig G, Wuster C, et al. A newly developed spine deformity
index (SDI) to quantitate vertebral crush fractures in patients with os-
teoporosis. Bone Miner 1988;3:335-49.
19. Gornbein JA, Lazaro CG, Little RJA. Incomplete data in repeated measures
analysis. Stat Methods Med Res 1992;1:275-95.
20. Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognized
problem in gastrointestinal tolerability. Osteoporos Int 1994;4:320-2.
21. Schiller JH, Rasmussen P, Benson AB III, et al. Maintenance etidronate in
the prevention of malignancy-associated hypercalcemia. Arch Intern Med
1987;147:963-6.
22. Lufkin EG, Wahner HW, O’Fallon WM, et al. Treatment of postmenopausal
osteoporosis with transdermal estrogen. Ann Intern Med 1992;117:1-9.
23. Riggs BL, Hodgson SF, O’Fallon WM, et al. Effect of ﬂuoride treatment on
the fracture rate in postmenopausal women with osteoporosis. N Engl J
Med 1990;322:802-9.
24. Kleerekoper M, Peterson EL, Nelson DA, et al. A randomized trial of so-
dium ﬂuoride as a treatment for postmenopausal osteoporosis. Osteoporos
Int 1991;1:155-61.
25. Pak CYC, Sakhaee K, Piziak V, et al. Slow-release sodium ﬂuoride in the
management of postmenopausal osteoporosis: a randomized controlled tri-
al. Ann Intern Med 1994;120:625-32.
26. Mamelle N, Meunier PJ, Dusan R, et al. Risk-beneﬁt ratio of sodium ﬂuo-
ride treatment in primary vertebral osteoporosis. Lancet 1988;2:361-5.
27. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate
treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-
9.
28. Storm T, Thamsborg G, Steiniche T, Genant HK, Sørensen OH. Effect of
intermittent cyclical etidronate therapy on bone mass and fracture rate in
women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-
71.
29. Tilyard MW, Spears GFS, Thomson J, Dovey S. Treatment of postmeno-
pausal osteoporosis with calcitriol or calcium. N Engl J Med 1992;326:357-
62.
30. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent
hip fractures in elderly women. N Engl J Med 1992;327:1637-42.
31. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin
given intranasally on bone mass and fracture rates in established osteoporo-
sis: a dose-response study. BMJ 1992;305:556-61.
32. Windeler J, Lange S. Events per person year — a dubious concept. BMJ
1995;310:454-6.
Table 4. Women Who Discontinued Therapy.
YEAR OF STUDY PLACEBO GROUP
(N  397)
ALENDRONATE GROUP (N  597)
5 mg
(N  202)
10 mg
(N  196)
20/5 mg
(N  199)
no. of women (%)
1 23 (5.8) 17 (8.4) 16 (8.2) 17 (8.5)
2 27 (6.8) 6 (3.0) 6 (3.1) 6 (3.0)
3 15 (3.8) 12 (5.9) 4 (2.0) 13 (6.5)
Total 65 (16.4) 35 (17.3) 26 (13.3) 36 (18.1)
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